Determination of the neuroprotective agent 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione in plasma using high-performance liquid chromatography.
A rapid, sensitive and selective high-performance liquid chromatographic method for the determination of the neuroprotectant 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione in rat plasma has been established and validated. Samples of 0.5 ml of plasma are extracted by elution from a Bond-Elut column with methanol and analysed on a reversed-phase column. The wavelength of UV detection is 254 nm. The method is linear at least up to 30 micrograms/ml, with a lowest reliable determination level of 4 mg/ml. The assays has a coefficient of variation of 13% at 10 ng/ml and 4% at 1000 ng/ml. Small variations in the extraction procedure and the liquid chromatographic conditions have minimal or no influence on the assay.
Nordholm
L
L
Department of Drug Metabolism, Novo Nordisk CNS Division, Målov, Denmark.
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D005260:Female; D009420:Nervous System / Q000187:drug effects*; D011810:Quinoxalines / Q000097:blood* / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline